Ruxolitinib CAS No. 941678-49-5 Antineoplastic Pharmaceutical Raw Material
introduce
Ruxolitinib is a potent oral JAK1/JAK2 dual tyrosine kinase inhibitor and core antineoplastic API. It selectively blocks JAK-STAT signaling pathway, inhibiting abnormal cell proliferation and inflammation. Approved for treating myelofibrosis, polycythemia vera, and graft-versus-host disease (GVHD).
Our products comply with strict international standards to ensure high purity, stable efficacy, and reliable supply for clinical use and biomedical research.
Physical and chemical properties
Ruxolitinib exhibits key physical and chemical characteristics supporting its pharmaceutical and research applications, as follows:
- Melting Point: 84-89 °C
- Density: 1.40±0.1 g/cm³
- Solubility: Soluble in DMSO (28mg/ml) and ethanol (heated slightly, 15mg/ml)
- Stability: Stable in DMSO or ethanol at -20°C for up to 3 months
1. Strong Targeting and Excellent Inhibitory Activity
As a highly selective JAK1/JAK2 inhibitor, it has potent inhibitory activity against JAK1 and JAK2, with over 130-fold selectivity for JAK1/JAK2 versus JAK3. Compared with non-selective kinase inhibitors, it can precisely block the JAK-STAT signaling pathway, reduce interference with other kinases, and achieve more targeted medication.
2. A Breakthrough Drug for Myelofibrosis Treatment
It is the world's first approved oral drug for myelofibrosis, compared with traditional symptomatic treatments, it can inhibit abnormal bone marrow proliferation and induce apoptosis of pathological cells from the pathogenesis level, significantly reduce the level of inflammatory factors in the body, and effectively improve core symptoms such as splenomegaly and anemia.
3. Wide Coverage of Myelofibrosis Types
It can be used for the treatment of all types of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis. It has stronger adaptability compared with treatment regimens only applicable to a single type of myelofibrosis.
4. Great Potential for Expanded Applications
In addition to the core indication, it has shown good efficacy in clinical studies of alopecia areata, psoriasis, arthritis and other diseases. Compared with similar drugs limited to the treatment of hematological diseases, it has more expandable application scenarios.
1. Core Indication
Used for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis. It can relieve symptoms such as splenomegaly, fatigue, bone pain and night sweats in patients.
2. Expanded Research Applications
(1) Used in clinical studies of alopecia areata treatment, which can significantly alleviate hair loss symptoms in most patients;
(2) Can be used for the treatment of psoriasis, and also shows effective anti-inflammatory effect in animal models of arthritis;
(3) Has anti-tumor and immunomodulatory activities, can inhibit the proliferation of JAK2V617F mutation-related cells, and plays a role in the treatment of myeloproliferative neoplasms.
We implement strict full-process quality control, with each batch of Ruxolitinib undergoing rigorous testing of key indicators including purity , solubility, stability, enantiomeric excess, and biological activity to meet standards.
Equipped with a stable raw material supply chain, we ensure continuous large-scale supply. Our professional technical team provides tailored services, including formulation optimization, application guidance, and post-sales technical support to address clinical and research needs.
As a first-in-class JAK1/JAK2 inhibitor, Ruxolitinib has revolutionized the treatment of myelofibrosis and other JAK-mediated diseases, offering significant clinical benefits to patients with limited therapeutic options. With its targeted mechanism, broad efficacy, convenient administration, and reliable supply capacity, we are committed to providing high-quality Ruxolitinib API and professional services for global pharmaceutical companies, research institutions, and clinical applications.
Choose our Ruxolitinib to meet your needs in pharmaceutical formulation, hematology research, and clinical treatment. Contact us for more product details and cooperation support.